Likewise, INI-678 (an HSD17B13 inhibitor), introduced by Inipharm, has demonstrated efficacy in decreasing liver fibrosis in a human liver-on-a-chip-model, opening a gate for broader application of small-molecule therapy in genetic-based precision medicine of NAFLD [189]. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatotic liver disease.